Amylin aims to raise over $200m
This article was originally published in Scrip
Executive Summary
Amylin Pharmaceuticals is seeking over $203.1 million from the sale of 13 million shares of its common stock, having priced the shares at $15.62 each. The offering is expected to close on or around 13 March.